These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice. Ganbaatar B; Fukuda D; Shinohara M; Yagi S; Kusunose K; Yamada H; Soeki T; Hirata KI; Sata M Eur J Pharmacol; 2020 May; 875():173040. PubMed ID: 32114052 [TBL] [Abstract][Full Text] [Related]
3. Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity. Liu Y; Xu J; Wu M; Xu B; Kang L Lipids Health Dis; 2021 Jan; 20(1):5. PubMed ID: 33436015 [TBL] [Abstract][Full Text] [Related]
4. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway. Meng Z; Liu X; Li T; Fang T; Cheng Y; Han L; Sun B; Chen L Int Immunopharmacol; 2021 May; 94():107492. PubMed ID: 33647823 [TBL] [Abstract][Full Text] [Related]
5. Empagliflozin improves primary haemodynamic parameters and attenuates the development of atherosclerosis in high fat diet fed APOE knockout mice. Dimitriadis GK; Nasiri-Ansari N; Agrogiannis G; Kostakis ID; Randeva MS; Nikiteas N; Patel VH; Kaltsas G; Papavassiliou AG; Randeva HS; Kassi E Mol Cell Endocrinol; 2019 Aug; 494():110487. PubMed ID: 31195080 [TBL] [Abstract][Full Text] [Related]
6. Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy. Lee YH; Kim SH; Kang JM; Heo JH; Kim DJ; Park SH; Sung M; Kim J; Oh J; Yang DH; Lee SH; Lee SY Am J Physiol Renal Physiol; 2019 Oct; 317(4):F767-F780. PubMed ID: 31390268 [TBL] [Abstract][Full Text] [Related]
7. Empagliflozin inhibits macrophage inflammation through AMPK signaling pathway and plays an anti-atherosclerosis role. Fu J; Xu H; Wu F; Tu Q; Dong X; Xie H; Cao Z Int J Cardiol; 2022 Nov; 367():56-62. PubMed ID: 35931206 [TBL] [Abstract][Full Text] [Related]
9. Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus. Kohlmorgen C; Gerfer S; Feldmann K; Twarock S; Hartwig S; Lehr S; Klier M; Krüger I; Helten C; Keul P; Kahl S; Polzin A; Elvers M; Flögel U; Kelm M; Levkau B; Roden M; Fischer JW; Grandoch M Diabetologia; 2021 Aug; 64(8):1834-1849. PubMed ID: 34131781 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice. Gangadharan Komala M; Gross S; Mudaliar H; Huang C; Pegg K; Mather A; Shen S; Pollock CA; Panchapakesan U PLoS One; 2014; 9(11):e108994. PubMed ID: 25369239 [TBL] [Abstract][Full Text] [Related]
11. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE Han JH; Oh TJ; Lee G; Maeng HJ; Lee DH; Kim KM; Choi SH; Jang HC; Lee HS; Park KS; Kim YB; Lim S Diabetologia; 2017 Feb; 60(2):364-376. PubMed ID: 27866224 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging. Kidokoro K; Cherney DZI; Bozovic A; Nagasu H; Satoh M; Kanda E; Sasaki T; Kashihara N Circulation; 2019 Jul; 140(4):303-315. PubMed ID: 30773020 [TBL] [Abstract][Full Text] [Related]
13. Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus. Luippold G; Klein T; Mark M; Grempler R Diabetes Obes Metab; 2012 Jul; 14(7):601-7. PubMed ID: 22268612 [TBL] [Abstract][Full Text] [Related]
14. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes. Cheng ST; Chen L; Li SY; Mayoux E; Leung PS PLoS One; 2016; 11(1):e0147391. PubMed ID: 26807719 [TBL] [Abstract][Full Text] [Related]
16. The sodium-glucose co-transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE-deficient mice with streptozotocin-induced diabetes. Iwamoto M; Kubota T; Sakurai Y; Wada N; Shioda S; Yamauchi T; Kadowaki T; Kubota N Pharmacol Res Perspect; 2022 Aug; 10(4):e00971. PubMed ID: 35707828 [TBL] [Abstract][Full Text] [Related]
17. Empagliflozin, a sodium glucose cotransporter-2 inhibitor, ameliorates peritoneal fibrosis via suppressing TGF-β/Smad signaling. Shentu Y; Li Y; Xie S; Jiang H; Sun S; Lin R; Chen C; Bai Y; Zhang Y; Zheng C; Zhou Y Int Immunopharmacol; 2021 Apr; 93():107374. PubMed ID: 33517222 [TBL] [Abstract][Full Text] [Related]
18. The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE Leng W; Ouyang X; Lei X; Wu M; Chen L; Wu Q; Deng W; Liang Z Mediators Inflamm; 2016; 2016():6305735. PubMed ID: 28104929 [No Abstract] [Full Text] [Related]
19. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation. Koyani CN; Plastira I; Sourij H; Hallström S; Schmidt A; Rainer PP; Bugger H; Frank S; Malle E; von Lewinski D Pharmacol Res; 2020 Aug; 158():104870. PubMed ID: 32434052 [TBL] [Abstract][Full Text] [Related]